LifeCycle: A better solution

Oral absorption of drugs with low water solubility is limited by the difficulty of formulating them so the drug molecules can penetrate the epithelium in the gastrointestinal tract. LifeCycle Pharma A/S, a spinout from specialty pharmaceutical company H. Lundbeck A/S, says its MeltDose formulation technology can improve the bioavailability of marketed drugs with poor solubility and create new IP around them.

In addition to technology from Lundbeck (CSE:LUN, Copenhagen, Denmark), LifeCycle received financing and personnel, including the inventors of MeltDose. After being spun out, LifeCycle also submitted about 50 patent applications covering the company's technology and products. ...